MA33290B1 - Pipéridines substituées - Google Patents

Pipéridines substituées

Info

Publication number
MA33290B1
MA33290B1 MA34375A MA34375A MA33290B1 MA 33290 B1 MA33290 B1 MA 33290B1 MA 34375 A MA34375 A MA 34375A MA 34375 A MA34375 A MA 34375A MA 33290 B1 MA33290 B1 MA 33290B1
Authority
MA
Morocco
Prior art keywords
diseases
substituted piperidines
treating
preventing
piperidines
Prior art date
Application number
MA34375A
Other languages
English (en)
Inventor
Dirk Heimbach
Susanne Roehrig
Grande Yolanda Cancho
Eckhard Bender
Katja Zimmermann
Anja Buchmueller
Christoph Gerdes
Mark Jean Gnoth
Kersten Matthias Gericke
Mario Jeske
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33290B1 publication Critical patent/MA33290B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

L'invention concerne de nouvelles pipéridines substituées, des procédés pour les produire, leur utilisation pour traiter et/ou prévenir des maladies, ainsi que leur utilisation pour produire des médicaments pour traiter et/ou prévenir des maladies, en particulier des maladies cardiovasculaires et des maladies tumorales.
MA34375A 2009-05-27 2010-05-19 Pipéridines substituées MA33290B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009022896A DE102009022896A1 (de) 2009-05-27 2009-05-27 Substituierte Piperidine
PCT/EP2010/003059 WO2010136144A1 (fr) 2009-05-27 2010-05-19 Pipéridines substituées

Publications (1)

Publication Number Publication Date
MA33290B1 true MA33290B1 (fr) 2012-05-02

Family

ID=42543057

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34375A MA33290B1 (fr) 2009-05-27 2010-05-19 Pipéridines substituées

Country Status (28)

Country Link
US (2) US20120220563A1 (fr)
EP (1) EP2435427A1 (fr)
JP (1) JP5718320B2 (fr)
KR (1) KR20120044289A (fr)
CN (2) CN102596944B (fr)
AR (1) AR076692A1 (fr)
AU (1) AU2010252345A1 (fr)
BR (1) BRPI1012055A2 (fr)
CA (1) CA2763400A1 (fr)
CL (1) CL2011002965A1 (fr)
CO (1) CO6470823A2 (fr)
CR (1) CR20110628A (fr)
CU (1) CU20110215A7 (fr)
DE (1) DE102009022896A1 (fr)
DO (1) DOP2011000364A (fr)
EA (1) EA201190312A1 (fr)
EC (2) ECSP11011483A (fr)
GT (1) GT201100300A (fr)
IL (1) IL215901A0 (fr)
MA (1) MA33290B1 (fr)
MX (1) MX2011012505A (fr)
PE (1) PE20120934A1 (fr)
SG (1) SG175753A1 (fr)
TN (1) TN2011000595A1 (fr)
TW (1) TW201109326A (fr)
UY (2) UY32636A (fr)
WO (1) WO2010136144A1 (fr)
ZA (1) ZA201108565B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022892A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DK2763979T3 (en) 2011-10-07 2019-04-01 Takeda Pharmaceuticals Co 1-arylcarbonyl-4-oxy-piperidine compounds for the treatment of neurodegenerative diseases
BR112018071548A2 (pt) 2016-04-20 2019-04-16 Bristol-Myers Squibb Company compostos heterocíclicos bicíclicos substituídos
JP7102404B2 (ja) 2016-11-03 2022-07-19 ブリストル－マイヤーズ スクイブ カンパニー 置換窒素含有化合物
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物
WO2023044364A1 (fr) 2021-09-15 2023-03-23 Enko Chem, Inc. Inhibiteurs de protoporphyrinogène oxydase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997036873A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines et hexahydro-1h-azepines declenchant la liberation de l'hormone de croissance
US6403612B2 (en) * 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
ES2276980T3 (es) 2001-10-15 2007-07-01 Janssen Pharmaceutica N.V. Derivados sustituidos de la 4-fenil-4-(1h-imidazol-2-il) piperidina para reducir el daño isquemico.
EP1480957A1 (fr) * 2002-03-01 2004-12-01 Smithkline Beecham Corporation Activateurs de hppars
CN1993128A (zh) * 2004-06-24 2007-07-04 因塞特公司 N－取代的哌啶及它们作为药物的用途
JP2008504275A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション Ｎ−置換ピペリジンおよびその医薬としての使用
NZ551602A (en) 2004-06-24 2010-11-26 Incyte Corp Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1778229A4 (fr) 2004-08-10 2009-06-17 Incyte Corp Composes amido et leur utilisation comme produits pharmaceutiques
JP2007008913A (ja) * 2004-09-17 2007-01-18 Tanabe Seiyaku Co Ltd ピペリジン化合物およびその製法
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004061750A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Heteroaryl-substituierte Pyrazoline
WO2007038138A2 (fr) 2005-09-21 2007-04-05 Incyte Corporation Utilisation pharmaceutique de composes amido
EA200870216A1 (ru) 2006-01-31 2009-02-27 Инсайт Корпорейшн Амидо соединения и их применение в качестве лекарственных средств
US20070213311A1 (en) 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US20070293529A1 (en) 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
DK2227466T3 (da) * 2007-11-30 2011-08-08 Bayer Schering Pharma Ag Heteroaryl-substituerede piperidiner
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine

Also Published As

Publication number Publication date
CN104744452A (zh) 2015-07-01
AR076692A1 (es) 2011-06-29
ZA201108565B (en) 2013-01-30
UY32636A (es) 2010-12-31
PE20120934A1 (es) 2012-08-01
US20110021489A1 (en) 2011-01-27
DOP2011000364A (es) 2012-02-29
CA2763400A1 (fr) 2010-12-02
ECSP11011482A (es) 2011-12-30
CU20110215A7 (es) 2012-03-15
CR20110628A (es) 2012-03-22
IL215901A0 (en) 2012-01-31
CO6470823A2 (es) 2012-06-29
TW201109326A (en) 2011-03-16
MX2011012505A (es) 2011-12-14
CN102596944A (zh) 2012-07-18
SG175753A1 (en) 2011-12-29
JP2012528090A (ja) 2012-11-12
TN2011000595A1 (en) 2013-05-24
DE102009022896A1 (de) 2010-12-02
EP2435427A1 (fr) 2012-04-04
CN102596944B (zh) 2015-08-26
WO2010136144A1 (fr) 2010-12-02
ECSP11011483A (es) 2011-12-30
EA201190312A1 (ru) 2012-05-30
UY32638A (es) 2010-10-29
BRPI1012055A2 (pt) 2016-05-17
CL2011002965A1 (es) 2012-07-06
GT201100300A (es) 2013-08-21
JP5718320B2 (ja) 2015-05-13
KR20120044289A (ko) 2012-05-07
US8084469B2 (en) 2011-12-27
US20120220563A1 (en) 2012-08-30
AU2010252345A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
MA33290B1 (fr) Pipéridines substituées
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY172372A (en) Compositions and methods for lowering triglycerides
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MX337933B (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MX2010003325A (es) Anticuepos novedosos.
MY159375A (en) Combinatorial therapy
MY161909A (en) Anti-her3 antibodies and uses thereof
WO2009068214A3 (fr) Pipéridines à substitution hétéroaryl
IN2012DN02737A (fr)
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MA33291B1 (fr) Pipéridines substituées
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
UA102115C2 (ru) Дизамещенные фталазиновые антагонисты сигнального пути hedgehog
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
WO2009115252A3 (fr) Pyrazolamides substitués et leur utilisation
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments